ArticleNature2025
Author Correction: FBP1 controls liver cancer evolution from senescent MASH hepatocytes.
Abstract readPublished Erratum
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum for
Authors and funding
23 authors.
Li Gu *Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA. ligu@scu.edu.cn.ORCID http://orcid.org/0000-0001-5812-9024
Yahui Zhu *School of Medicine, Chongqing University, Chongqing, China. zhuyahui861106@foxmail.com.ORCID http://orcid.org/0000-0002-8138-0011
Shuvro P NandiDepartment of Cellular and Molecular Medicine, UCSD, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-4855-4697
Maiya LeeLaboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.
Kosuke WatariLaboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-0260-2323
Breanna BarengLaboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.
Masafumi OhiraLaboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-0775-3390
Yuxiao LiuLaboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.
Sadatsugu SakaneDivision of Endocrinology & Metabolism, UCSD, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-6306-4621
Rodrigo CarlessiCurtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia.ORCID http://orcid.org/0000-0003-0038-7391
Consuelo SaucedaDepartment of Pharmacology, UCSD, La Jolla, CA, USA.
Debanjan DharDepartment of Medicine, UCSD, La Jolla, CA, USA.
Souradipta GangulyDepartment of Medicine, UCSD, La Jolla, CA, USA.
Mojgan HosseiniDepartment of Pathology, UCSD, La Jolla, CA, USA.
Marcos G TenecheSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-4785-7987
Peter D AdamsSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-0684-1770
David J GonzalezDepartment of Pharmacology, UCSD, La Jolla, CA, USA.
Tatiana KisselevaDivision of Endocrinology & Metabolism, UCSD, La Jolla, CA, USA.
Liver Cancer Collaborative
Janina E E Tirnitz-ParkerCurtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia.ORCID http://orcid.org/0000-0002-3558-5892
M Celeste SimonAbramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-9106-447X
Ludmil B AlexandrovDepartment of Cellular and Molecular Medicine, UCSD, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-3596-4515
Michael KarinLaboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA. karinoffice@ucsd.edu.ORCID http://orcid.org/0000-0002-2758-6473
Funding
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9MUC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4MSan Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8MMetabolic Tumor Suppressors in Renal Cancer: Unprecedented Roles in Disease ProgressionR35CA220483 · NCI · UNIVERSITY OF PENNSYLVANIA · PI M. CELESTE SIMON · 2017 to 2026
$9.4MRole of hypernutrition and metabolic stress in non-alcoholic steatohepatitis (NASH) driven hepatocellular carcinoma (HCC)P01CA281819 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Pablo Tamayo · 2024 to 2026
$9.2MInactivation of Hepatic Stellate Cells During Reversal of Liver FibrosisR01DK099205 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRENNER, DAVID A., KISSELEVA, TATIANA · 2014 to 2025
$4.8MControl of Lipogenesis and Hepatic Steatosis by Caspase-2R01DK120714 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Karin · 2019 to 2026
$4.0MThe NRF2-FBP1 crossregulatory loop and the control of healthy and diseased liver metabolismR01DK133448 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Karin, Jun Hee Lee · 2022 to 2026
$3.6MDetecting Mutational Signatures of Environmental Mutagens in Heathy Individuals for Personalized Cancer PreventionR01ES032547 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ALEXANDROV, LUDMIL B · 2021 to 2025
$3.4MHighly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitorsR01CA234128 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KARIN, MICHAEL · 2019 to 2023
$2.7MMutational Signatures of a Combined Environmental Exposure: Arsenic and Ultraviolet RadiationR01ES030993 · NIEHS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI HUDSON, LAURIE G, LIU, KE JIAN · 2020 to 2024
$2.5MA new mouse model for studying the pathogenesis and immunobiology of intrahepatic cholangiocarcinoma and improving its immunotherapyR01CA281784 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Karin · 2023 to 2026
$2.5MNCATS NIH HHS KL2 TR001444NCI NIH HHS P01 CA281819NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA234128NCI NIH HHS R01 CA269919NCI NIH HHS R01 CA281784NCI NIH HHS R35 CA220483NIDDK NIH HHS P30 DK120515NIDDK NIH HHS R01 DK099205NIDDK NIH HHS R01 DK120714NIDDK NIH HHS R01 DK133448NIEHS NIH HHS R01 ES030993NIEHS NIH HHS R01 ES032547NIH HHS S10 OD032398
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.